Literature DB >> 16369533

Nras loss induces metastatic conversion of Rb1-deficient neuroendocrine thyroid tumor.

Chiaki Takahashi1, Bernardo Contreras, Tsuyoshi Iwanaga, Yujiro Takegami, Anke Bakker, Roderick T Bronson, Makoto Noda, Massimo Loda, Jennifer L Hunt, Mark E Ewen.   

Abstract

Mutations in the gene encoding the retinoblastoma tumor suppressor predispose humans and mice to tumor development. Here we have assessed the effect of Nras loss on tumor development in Rb1 heterozygous mice. Loss of one or two Nras alleles is shown to significantly reduce the severity of pituitary tumors arising in Rb1(+/-) animals by enhancing their differentiation. By contrast, C-cell thyroid adenomas occurring in Rb1(+/-) mice progress to metastatic medullary carcinomas after loss of Nras. In Rb1(+/-)Nras(+/-) animals, distant medullary thyroid carcinoma metastases are associated with loss of the remaining wild-type Nras allele. Loss of Nras in Rb1-deficient C cells results in elevated Ras homolog family A (RhoA) activity, and this is causally linked to the invasiveness and metastatic behavior of these cells. These findings suggest that the loss of the proto-oncogene Nras in certain cellular contexts can promote malignant tumor progression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16369533     DOI: 10.1038/ng1703

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  23 in total

Review 1.  Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality.

Authors:  Frederick Bauzon; Liang Zhu
Journal:  Cell Cycle       Date:  2010-06-01       Impact factor: 4.534

2.  Wild-type NRas and KRas perform distinct functions during transformation.

Authors:  Poppy P Fotiadou; Chiaki Takahashi; Hasan N Rajabi; Mark E Ewen
Journal:  Mol Cell Biol       Date:  2007-07-16       Impact factor: 4.272

3.  ATM mediates pRB function to control DNMT1 protein stability and DNA methylation.

Authors:  Awad Shamma; Misa Suzuki; Naoyuki Hayashi; Masahiko Kobayashi; Nobunari Sasaki; Takumi Nishiuchi; Yuichiro Doki; Takahiro Okamoto; Susumu Kohno; Hayato Muranaka; Shunsuke Kitajima; Ken-Ichi Yamamoto; Chiaki Takahashi
Journal:  Mol Cell Biol       Date:  2013-06-10       Impact factor: 4.272

4.  p66(Shc) restrains Ras hyperactivation and suppresses metastatic behavior.

Authors:  Z Ma; Z Liu; R-F Wu; L S Terada
Journal:  Oncogene       Date:  2010-08-02       Impact factor: 9.867

5.  Neurocutaneous melanocytosis (melanosis).

Authors:  Martino Ruggieri; Agata Polizzi; Stefano Catanzaro; Manuela Lo Bianco; Andrea D Praticò; Concezio Di Rocco
Journal:  Childs Nerv Syst       Date:  2020-10-13       Impact factor: 1.475

6.  Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice.

Authors:  Hongbo Wang; Frederick Bauzon; Peng Ji; Xiaoliang Xu; Daqian Sun; Joseph Locker; Rani S Sellers; Keiko Nakayama; Keiich I Nakayama; David Cobrinik; Liang Zhu
Journal:  Nat Genet       Date:  2009-12-06       Impact factor: 38.330

Review 7.  Clinical and molecular genetics of acromegaly: MEN1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors.

Authors:  Anelia Horvath; Constantine A Stratakis
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

Review 8.  Thyroid C-Cell Biology and Oncogenic Transformation.

Authors:  Gilbert J Cote; Elizabeth G Grubbs; Marie-Claude Hofmann
Journal:  Recent Results Cancer Res       Date:  2015

9.  Growth arrest signaling of the Raf/MEK/ERK pathway in cancer.

Authors:  Jong-In Park
Journal:  Front Biol (Beijing)       Date:  2014-02

10.  Perturbation biology: inferring signaling networks in cellular systems.

Authors:  Evan J Molinelli; Anil Korkut; Weiqing Wang; Martin L Miller; Nicholas P Gauthier; Xiaohong Jing; Poorvi Kaushik; Qin He; Gordon Mills; David B Solit; Christine A Pratilas; Martin Weigt; Alfredo Braunstein; Andrea Pagnani; Riccardo Zecchina; Chris Sander
Journal:  PLoS Comput Biol       Date:  2013-12-19       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.